Some people infected with HIV are teeming with virus, but don’t get sick. Their resistive powers probably come from a mix of ...
HIV Research for Prevention Conference ANALYSIS | SETHI NCUBE | The 5th HIV Research for Prevention Conference (HIVR4P 2024) ...
GlobalData on MSN1d
Gilead and MSD to advance once-weekly HIV treatment to Phase IIIThe companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.
The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for ...
From an anal PrEP douche to the first women-controlled HIV prevention product, here's all the new HIV prevention products ...
From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...
Gilead and Merck said their once-weekly pill to treat HIV resulted in a comparable level of viral suppression compared to a ...
The data presented indicate a favorable gut bile acid profile which may contribute to ibezapostat's beneficial anti-recurrence effect in patients with C. difficile Infection (CDI)Ibezapolstat ...
Q: How worried should I be about infections that cause cancer? A: Cancers caused by infections are quite common. A recent ...
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
ATLANTA — Thousands of people gathered in Atlanta on Saturday morning to help keep awareness for AIDS top of mind as ...
Don, a Philadelphia resident, who requested not to share his last name, remembers when he was first diagnosed with HIV in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback